Open an account

Evofem Biosciences

EVFM · OTC

$0.0063+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.0063

About EVFM

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes products to women's sexual and reproductive health. The company is headquartered in San Diego, California and currently employs 29 full-time employees. The company went IPO on 2014-11-20. The firm is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. The company comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The firm also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.

Employees
29
Headquarters
San Diego, California
Listed
Nov 20, 2014
Sector
Health Care
Industry
Pharmaceuticals
Website
evofem.com

EVFM key statistics

Market cap
834.94K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
132.82K
Volume
44.77K
Open price
$0.0063
High today
$0.0064
Low today
$0.0063
52 Week high
$0.02
52 Week low
$0.0008

Evofem Biosciences (EVFM) at a glance

As of Oct 20, 2026, Evofem Biosciences (EVFM) shares are priced at $0.0063, giving the company a market cap of 834.94K and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.0063 and $0.0064. The current price is 0.0% above the day's low and 1.6% below its high.

Volume so far is 44.77K shares, below the average of 132.82K shares a day.

Over the past year Evofem Biosciences has ranged from $0.0008 to $0.02, and now sits 29% of the way up that range.

Evofem Biosciences met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q4 FY24 it reported -$0.03 per share against an estimate of $0.00.

EVFM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 95.7% on average.

  1. Q4 FY21: reported -$618.75 per share against an estimate of -$435.09
  2. Q1 FY22: reported -$360.00 per share against an estimate of -$382.50
  3. Q2 FY22: reported -$571.25 per share against an estimate of -$124.95
  4. Q3 FY22: reported -$5.00 per share against an estimate of -$31.88
  5. Q4 FY22: reported -$38.75 per share against an estimate of -$26.77
  6. Q3 FY23: reported $0.10 per share against an estimate of -$0.0612
  7. Q4 FY23: reported -$0.44 per share against an estimate of -$0.6222
  8. Q4 FY24: reported -$0.03 per share against an estimate of $0.00

EVFM news

  • Press releasePRNewswire

    Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE

  • Press releasePRNewswire

    Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update

  • Press releasePRNewswire

    Evofem Announces Voting Results from Special Meeting of Stockholders

  • Press releasePRNewswire

    Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates

  • Press releasePRNewswire

    Evofem Biosciences Honors World Contraception Day

  • Press releasePRNewswire

    Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

  • Press releasePRNewswire

    Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

  • Press releasePRNewswire

    Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

Similar companies

Companies in the same industry as Evofem Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.